Active for Obesity

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Obesity+1 MoreLorcaserin HCl - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will investigate the effect of lorcaserin on the brain's control of appetite and metabolism.

Eligible Conditions
  • Obesity
  • Weight Loss

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 6 months

28 days
fMRI (Functional changes in the brain)
6 months
Body Composition (DEXA)
Metabolic Rate (Resting Metabolic Rate (RMR)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Active
1 of 2
Placebo
1 of 2

Active Control

Non-Treatment Group

40 Total Participants · 2 Treatment Groups

Primary Treatment: Active · Has Placebo Group · Phase 4

Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Active
Drug
ActiveComparator Group · 1 Intervention: Lorcaserin HCl · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor
777 Previous Clinical Trials
844,340 Total Patients Enrolled
20 Trials studying Obesity
590 Patients Enrolled for Obesity
Christos S Mantzoros, MD DScPrincipal InvestigatorBeth Israel Deaconess Medical Center

Eligibility Criteria

Age 18 - 65 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: